Fact-checked by Grok 2 weeks ago

OSAS

Obstructive sleep apnea syndrome (OSAS) is a prevalent sleep-related defined by recurrent episodes of partial or complete upper airway during , leading to apneas (complete cessation of for at least 10 seconds) or hypopneas (partial reduction with oxygen desaturation or arousal), often accompanied by and other symptoms that impair daily functioning. Globally, OSAS affects an estimated 425 million adults aged 30 to 69 years with moderate-to-severe disease, representing a significant concern due to its underdiagnosis and association with comorbidities. In the United States, prevalence is approximately 25-30% among men and 9-17% among women, with higher rates observed in certain ethnic groups such as Hispanics, Blacks, and Asians. Risk factors include (with strongly correlating to severity), male sex, advancing age, anatomical features like enlarged tonsils or a narrow airway, family history, , , and conditions such as or . The underlying involves reduced pharyngeal during , generating negative intraluminal that promotes airway , exacerbated by factors like alcohol use or sedatives. Common symptoms of OSAS include loud , observed breathing pauses or choking episodes during , frequent nocturnal awakenings, morning headaches, dry mouth upon waking, and profound daytime or drowsiness that interferes with concentration, , and . typically relies on , the gold standard that measures the apnea-hypopnea index (AHI)—with mild OSAS defined as 5-15 events per hour, moderate as 15-30, and severe as over 30—though home testing may suffice for uncomplicated cases. Untreated OSAS heightens risks for cardiovascular complications like , arrhythmias, , and ; metabolic issues including ; increased surgical and driving accident risks; and even worsened outcomes in infections such as COVID-19. Treatment for OSAS centers on (CPAP) therapy, which delivers pressurized air via a to maintain airway patency and is considered the most effective option for reducing AHI and improving symptoms, though adherence remains a challenge. Adjunctive strategies include for obese patients, oral appliances to advance the , positional therapy to avoid sleeping, and surgical interventions such as or stimulation for select cases refractory to conservative measures. Lifestyle modifications like , alcohol avoidance, and optimized are essential for prevention and management. With appropriate treatment, prognosis is generally favorable in the short term, alleviating symptoms and mitigating risks, though long-term outcomes depend on sustained adherence and may still involve reduced if cardiovascular comorbidities persist.

Definition and Classification

Overview and Terminology

Obstructive sleep apnea syndrome (OSAS), commonly abbreviated as OSA, is a prevalent sleep-related breathing disorder defined by recurrent episodes of partial or complete upper airway obstruction during , resulting in apneas (complete cessation of for at least 10 seconds) or hypopneas (partial reduction accompanied by or desaturation), alongside frequent arousals that fragment quality. These events occur despite ongoing respiratory effort, leading to intermittent and . OSAS affects millions worldwide and is linked to significant health risks, including cardiovascular complications, though its core pathology centers on anatomical and neuromuscular factors promoting airway collapsibility. The terminology of OSAS reflects its mechanistic and clinical features: "obstructive" denotes the mechanical blockage or collapse of the pharyngeal airway, distinguishing it from non-mechanical causes of pauses. "" originates from the Greek term apnoia, meaning "without breath" or "suspension of ," combining the prefix a- (absence) with pnoia (). The of "" underscores the constellation of associated symptoms, such as and daytime hypersomnolence, rather than a single isolated event; this derives from the Greek syndromē, signifying "a running together" or concurrence of signs. OSAS differs fundamentally from central sleep apnea (CSA), in which pauses in breathing arise from absent or diminished respiratory effort due to central nervous system dysfunction, without upper airway obstruction. Mixed sleep apnea, by contrast, involves a sequence beginning as central (no effort) and transitioning to obstructive (effort against blockage), often emerging in patients initially diagnosed with OSAS. In OSAS specifically, thoracoabdominal movements persist during obstructive events, highlighting the role of continued ventilatory drive against a compromised airway. In the International Classification of Sleep Disorders, Third Edition (ICSD-3), OSAS is categorized under sleep-related breathing disorders, emphasizing its diagnostic reliance on polysomnographic evidence of obstructive events. This classification framework aids in distinguishing OSAS from other breathing disturbances while noting its variable severity, typically assessed via the apnea-hypopnea index, and common manifestations like excessive daytime sleepiness.

Types and Severity Levels

Obstructive sleep apnea syndrome (OSAS) is primarily classified into several types based on clinical presentation and associated conditions. The most common form is primary OSAS, which occurs in both adults and children and is characterized by recurrent upper airway obstruction without an identifiable underlying syndrome. In adults, primary OSAS often stems from multifactorial anatomical and physiological factors leading to isolated airway collapse during sleep. Pediatric primary OSAS, by contrast, frequently involves as the predominant cause, though it shares the core mechanism of partial or complete airway obstruction. Another variant is positional OSAS, where episodes of apnea and predominantly occur in the sleeping position due to gravitational effects exacerbating airway collapse, while symptoms are milder or absent in lateral positions. This type accounts for a significant proportion of cases in both adults and children, with prevalence estimates reaching up to 60% in pediatric cohorts undergoing . Syndrome-specific forms of OSAS include those linked to (OHS), where severe (typically BMI >30 kg/m²) combines with chronic and nocturnal , often amplifying OSAS severity through reduced respiratory drive and chest wall mechanics. OHS-associated OSAS is particularly prevalent in adults with morbid and requires integrated management beyond standard OSAS therapy. Severity of OSAS is standardized using the apnea-hypopnea index (AHI), calculated as the total number of apneas and hypopneas per hour of sleep:
\text{AHI} = \frac{\text{number of apneas + number of hypopneas}}{\text{total sleep time in hours}}
This metric quantifies the frequency of respiratory events, with apneas defined as ≥90% airflow reduction for ≥10 seconds and hypopneas as ≥30% reduction accompanied by ≥3% oxygen desaturation or arousal. In adults, severity is graded as mild (AHI 5–14.9 events/hour), moderate (15–29.9 events/hour), and severe (≥30 events/hour), thresholds established by the American Academy of Sleep Medicine (AASM) to guide treatment intensity. For children, lower thresholds reflect physiological differences, with mild OSAS defined as AHI 1–4.9 events/hour, moderate as 5–9.9 events/hour, and severe as ≥10 events/hour, emphasizing early intervention to prevent neurocognitive impacts.
Pediatric classification often incorporates the respiratory disturbance index (RDI), which extends AHI by including respiratory effort-related arousals (RERAs)—subtle airflow limitations causing EEG arousals without significant desaturation. RDI thus provides a more comprehensive assessment in children, where RERAs contribute substantially to total respiratory disturbances, potentially elevating severity grading beyond AHI alone. Factors such as the oxygen desaturation index (ODI)—the number of ≥3% desaturations per hour—further influence classification, as higher ODI values (>15 events/hour) correlate with increased cardiovascular risk and may prompt reclassification to severe even if AHI is borderline. These metrics collectively ensure severity reflects both event frequency and physiological burden.

Signs and Symptoms

In Adults

In adults, obstructive sleep apnea syndrome (OSAS) manifests through a range of nocturnal symptoms that disrupt continuity. Common presentations include loud , which is often disruptive to bed partners, and witnessed apneas or pauses in breathing during . Additional nocturnal disturbances encompass choking or gasping episodes upon arousal, (frequent awakenings to urinate, typically two or more times per night), and characterized by difficulty maintaining . These symptoms arise from repeated upper airway obstructions, leading to fragmented sleep architecture. Daytime symptoms in adults with OSAS primarily revolve around excessive sleepiness and impaired functioning, often quantified using the (), a validated self-report assessing the likelihood of dozing in eight common situations, with scores above 10 indicating significant sleepiness. is prevalent, alongside cognitive impairments such as poor concentration, reduced attention, and . Mood disturbances are also common, including irritability, anxiety, and depression, which can exacerbate daily challenges like work performance or driving safety. These manifestations correlate with OSAS severity, as measured by the apnea-hypopnea index. Gender differences influence symptom reporting in OSAS, with women often underdiagnosed due to presentations. Men more frequently exhibit classic signs like loud and witnessed apneas, while women tend to report , , morning headaches, and mood disorders such as over respiratory symptoms. This discrepancy contributes to delayed in females, who may seek care for nonspecific complaints.

In Children

In children, manifests through distinct nocturnal and daytime symptoms that can significantly impact development, differing from adult presentations where excessive daytime is more prominent. Unlike adults, pediatric patients frequently display hyperactivity rather than overt sleepiness, which can lead to misdiagnosis as attention-deficit/hyperactivity disorder (ADHD). Nocturnal symptoms are hallmark features and include loud , which affects 3-12% of children and often accompanies due to partial airway obstruction. Restless with frequent awakenings and paradoxical inward chest movements may occur as the child struggles against . Bedwetting, or secondary , is prevalent in affected children, serving as a key indicator that warrants screening for OSAS. Daytime symptoms in pediatric OSAS primarily involve neurobehavioral changes, such as hyperactivity, inattention, and , which mimic ADHD and contribute to poor school performance. Growth retardation, or failure-to-thrive, is another critical indicator, resulting from increased energy expenditure due to and disrupted secretion during sleep. These effects underscore the developmental vulnerabilities in children compared to the cardiovascular focus in adults. The most common etiology in children is adenotonsillar , where enlarged tonsils and adenoids—peaking between ages 2 and 8 due to —obstruct the airway during sleep. has emerged as a significant , with fat deposits around the upper airway increasing collapse propensity; each kg/m² increase in above the 50th raises OSAS risk by approximately 12%. This combination of anatomical and emerging metabolic factors highlights the need for early identification in pediatric populations.

Causes and Risk Factors

Anatomical and Structural Factors

Obstructive sleep apnea syndrome (OSAS) is frequently associated with craniofacial abnormalities that narrow the upper airway and promote collapse during sleep. Retrognathia, characterized by a posteriorly displaced , reduces the posterior airway space and increases pharyngeal collapsibility, thereby elevating OSAS risk. Micrognathia, or an underdeveloped , similarly contributes by limiting the structural support for the and , leading to airway encroachment. Enlarged tongue volume or , along with an elongated or thickened , further crowds the pharyngeal space, impeding airflow. Nasal obstruction, often due to deviated or turbinate , exacerbates these issues by increasing upstream resistance and forcing , which destabilizes the oropharynx. Soft tissue abnormalities play a central role in airway narrowing, particularly in the context of obesity-related pharyngeal fat deposition. Excess around the , including parapharyngeal fat pads, enlarges neck circumference and exerts lateral pressure on the airway walls, promoting collapsibility independent of overall in some cases. Tonsillar and adenoidal , common in both children and adults, significantly reduces the cross-sectional area of the oropharynx, with studies showing larger tonsillar volumes in OSAS patients compared to controls. Certain anatomical syndromes heighten OSAS susceptibility through inherent structural defects. is linked to a higher prevalence of OSAS due to midface , , and that compromise airway patency. , featuring micrognathia and posterior tongue displacement (glossoptosis), creates a functionally obstructed airway from birth, often necessitating early intervention. Airway collapsibility, a key structural vulnerability in OSAS, can be evaluated through non-invasive methods that highlight anatomical predisposition. The Mueller maneuver, involving forced inspiration against a closed and , visually assesses pharyngeal collapse during , correlating with OSAS severity. Cephalometric imaging measures skeletal relationships, such as mandibular plane angle and posterior airway space, identifying retrognathia or reduced hyoid position as risk indicators. These assessments underscore static defects without relying on dynamic physiological changes.

Physiological, Genetic, and Lifestyle Factors

Physiological factors play a significant in the development of syndrome (OSAS), particularly through changes that affect upper airway stability during . Aging contributes to OSAS risk by causing a progressive loss of pharyngeal dilator , which reduces the ability of airway muscles to maintain patency against collapsing forces. Hormonal influences, such as those occurring during in women, further exacerbate this vulnerability; postmenopausal hormonal shifts, including decreased and progesterone levels, are associated with increased OSAS prevalence due to diminished protective effects on respiratory control and muscle function. Endocrine disorders, including , , (PCOS), and , are associated with increased OSAS risk due to effects on airway anatomy, such as and in hypothyroidism, or fat distribution and soft tissue growth in acromegaly and Cushing's. Additionally, the use of and sedatives promotes excessive relaxation of upper airway muscles, heightening the likelihood of obstruction; alcohol consumption, for instance, has been shown to increase OSAS risk by approximately 25% through enhanced collapsibility. Genetic factors contribute to OSAS susceptibility via familial predisposition and specific polymorphisms that influence and airway responsiveness. OSAS exhibits a heritable component, with studies indicating that genetic factors account for a substantial portion of variability in disease occurrence, often manifesting as familial aggregation of cases. Polymorphisms in genes such as TNF-α, particularly the -308G/A variant, have been linked to elevated in the upper airway, increasing OSAS ; meta-analyses confirm that the A serves as a potential for disease development. Lifestyle factors represent modifiable contributors to OSAS, often amplifying physiological vulnerabilities. is a primary lifestyle-related risk, where excess , especially around the , narrows the airway; a greater than 17 inches in men or 16 inches in women is an established threshold for heightened risk. exacerbates this by inducing airway and , which thickens mucosal tissues and promotes obstruction, thereby worsening OSAS severity. The sleeping position further increases risk by allowing gravity to facilitate and collapse into the airway, a factor particularly relevant in position-dependent OSAS cases. Ethnic variations influence OSAS prevalence through interactions with physiological and genetic elements, notably craniofacial traits. For example, Asian populations exhibit higher OSAS rates at lower body mass indices compared to Caucasians, attributable to inherent craniofacial structures that predispose to earlier airway narrowing.

Pathophysiology

Mechanisms of Airway Collapse

Obstructive sleep apnea syndrome (OSAS) involves recurrent episodes of partial or complete upper airway obstruction during , primarily due to the of pharyngeal structures under specific physiological conditions. This arises from an imbalance between forces promoting airway patency and those favoring obstruction, exacerbated by -induced changes in and respiratory dynamics. Key mechanisms include alterations in upper airway dilator muscle activity, intraluminal pressure fluctuations, cyclical arousals, and instability in ventilatory control. During sleep, particularly in rapid (REM) sleep, there is a significant reduction in the tone of the muscle, the primary dilator of the upper airway, leading to pharyngeal narrowing and increased collapsibility. This is more pronounced in REM sleep compared to non-REM stages, as neural drive to upper airway muscles diminishes, allowing the tongue base to fall posteriorly and narrow the retrolingual space. Studies have shown that genioglossus electromyographic activity can decrease by up to 50-70% during phasic REM sleep in OSAS patients, directly contributing to airway instability. Anatomical risk factors, such as or craniofacial abnormalities, can predispose individuals to this effect by further compromising baseline airway dimensions. Negative pressure dynamics play a central role in precipitating collapse, governed by the principle, which describes how increased airflow velocity through a narrowed segment reduces intraluminal , promoting of compliant pharyngeal walls inward. In OSAS, inspiratory efforts generate high-velocity past partially obstructed sites, creating subatmospheric that exceeds the structural support of the airway tissues. This can be quantified by the simplified Bernoulli equation for : \Delta P = \frac{1}{2} \rho v^2 where \Delta P is the pressure drop, \rho is air density, and v is flow velocity; in narrowed airways, velocities often exceeding 10 m/s contribute to significant negative pressures via this mechanism, which, combined with respiratory muscle efforts, can result in total collapsing pressures of -20 to -50 cmH₂O sufficient to overcome dilator muscle resistance. The arousal cycle perpetuates OSAS events through a feedback loop where airway obstruction leads to hypoxia and hypercapnia, which stimulate chemoreceptors and trigger sympathetic nervous system activation, culminating in brief cortical arousals that temporarily restore airway patency. These arousals, often lasting 3-15 seconds, involve surges in sympathetic outflow, increasing heart rate and blood pressure by 10-30 mmHg per event, but they fragment sleep without resolving the underlying instability. Hypoxia and hypercapnia thresholds for arousal are heightened in chronic OSAS, prolonging apneic episodes until severe desaturation (e.g., SaO₂ <80%) occurs. Instability in respiratory control, quantified by elevated loop gain, further amplifies airway collapse by causing overshoots in ventilatory drive following arousals, leading to hypocapnia and subsequent central pauses that promote re-obstruction. Loop gain represents the sensitivity of the chemoreflex loop, where values greater than 1 indicate instability; in patients, loop gain is often 20-50% higher than in controls, particularly during non-REM sleep, contributing to the waxing-waning pattern of respiratory effort. Seminal modeling studies have established that high loop gain interacts with anatomical collapsibility to sustain the apnea-hypopnea cycle, with therapeutic implications for stabilizing ventilatory feedback.

Immediate and Systemic Effects

In obstructive sleep apnea syndrome (OSAS), repeated episodes of upper airway obstruction lead to immediate physiological disruptions, primarily intermittent hypoxia and hypercapnia, where oxygen desaturation alternates with reoxygenation and carbon dioxide levels rise during apneic events. These cycles trigger acute sympathetic nervous system activation, resulting in acute surges in blood pressure, typically increasing systolic BP by about 10-30 mmHg during arousals from sleep. Concurrently, the frequent arousals fragment sleep architecture, markedly reducing slow-wave sleep (stage N3) and overall sleep efficiency, which contributes to non-restorative sleep and daytime fatigue. Systemically, these immediate effects cascade into broader pathophysiological changes, including heightened oxidative stress from reactive oxygen species generated during hypoxia-reoxygenation cycles, which damages cellular structures and promotes inflammation. This oxidative burden impairs endothelial function, reducing nitric oxide bioavailability and fostering vascular stiffness, while chronic sympathetic overactivity exacerbates insulin resistance by altering glucose uptake in peripheral tissues. The interplay of these mechanisms amplifies metabolic dysregulation, with studies showing elevated fasting insulin levels in OSAS patients independent of obesity. Cardiovascular strain manifests acutely through arrhythmias, such as , often triggered by vagal nerve interruptions during apneic events that disrupt normal cardiac rhythm. Negative intrathoracic pressure generated by respiratory efforts against the obstructed airway further promotes atrial stretching and electrical instability, increasing arrhythmia incidence during sleep. Neuroendocrine responses include elevated cortisol levels due to hypothalamic-pituitary-adrenal axis activation from recurrent arousals and hypoxia, contributing to a hypercortisolemic state observed in moderate-to-severe OSAS. Additionally, growth hormone secretion is suppressed in affected individuals, impairing anabolic processes and muscle repair.

Diagnosis

Clinical Assessment and Screening

Clinical assessment for (OSAS) begins with a comprehensive evaluation to identify individuals at risk, guiding the need for further diagnostic testing. This initial step involves gathering a detailed sleep history and performing a targeted physical examination to detect symptoms and anatomical features suggestive of OSAS, without relying on laboratory confirmation. History taking focuses on eliciting key symptoms through patient and partner reports. Common inquiries include the presence of loud snoring, witnessed apneas or breathing pauses during sleep, nocturnal gasping or choking, excessive daytime sleepiness, and unrefreshing sleep. Associated medical conditions such as hypertension, particularly when unexplained, serve as important red flags indicating potential OSAS. Partner observations of apneas or restlessness are particularly valuable, as patients may be unaware of these events. Validated questionnaires enhance the efficiency of history taking by quantifying risk. The , a concise eight-item tool, assesses snoring (S), tiredness during the day (T), observed apneas (O), high blood pressure (P), body mass index greater than 35 kg/m² (B), age over 50 years (A), neck circumference greater than 40 cm (N), and male gender (G). Each affirmative response scores one point; a score of 3 or higher indicates high risk for moderate to severe , with sensitivity up to 93% for apnea-hypopnea index () ≥5 events/hour. The () evaluates excessive daytime sleepiness by asking patients to rate their likelihood of dozing (0-3 scale) in eight common situations, yielding a total score from 0 to 24; scores above 10 suggest abnormal sleepiness, though its sensitivity for OSAS detection ranges from 27% to 72%. These tools are recommended for screening but not for definitive diagnosis. Physical examination targets anatomical and physiological indicators of upper airway obstruction. Body mass index (BMI) is calculated to identify obesity, a major risk factor, while neck circumference is measured at the level of the thyroid cartilage, with values exceeding 40 cm signaling increased OSAS likelihood. The Mallampati score, performed with the patient seated and mouth maximally opened without phonation, classifies oropharyngeal visibility into four classes (I-IV); classes III and IV, indicating reduced airway space due to tongue or soft tissue prominence, independently predict OSAS presence and severity. These assessments help stratify risk and inform referral for confirmatory testing.

Polysomnography and Alternative Tests

Polysomnography (PSG) serves as the gold standard diagnostic test for (OSAS) in adults, involving an attended overnight study in a sleep laboratory to monitor multiple physiological parameters. It records electroencephalography (EEG) to determine sleep stages, airflow using nasal pressure transducers and thermistors, respiratory effort via thoracic and abdominal belts, pulse oximetry for oxygen saturation, electrocardiography for heart rate, and electromyography for muscle activity and arousals. From these measurements, the (AHI) is calculated as the total number of apneas and hypopneas per hour of sleep, while the (ODI) quantifies desaturation events per hour, providing objective quantification of respiratory disturbances. The (AASM) recommends PSG for all patients with clinical suspicion of OSAS, particularly those with comorbidities such as significant cardiorespiratory disease, neuromuscular disorders, chronic opioid use, history of stroke, or severe insomnia, where it can detect coexisting sleep disorders like central sleep apnea or hypoventilation. Home sleep apnea testing (HSAT) offers a more accessible alternative to PSG for diagnosing in uncomplicated adults, utilizing portable, unattended devices conducted at home to measure a subset of parameters including airflow, oxygen saturation, respiratory effort, and sometimes heart rate. These Type III or Type IV devices estimate the respiratory event index (REI) based on total recording time rather than sleep time, as they lack EEG for sleep staging, which limits their ability to detect arousals or non-respiratory sleep disturbances. AASM guidelines endorse HSAT for adults with a high pretest probability of moderate to severe (e.g., those with excessive daytime sleepiness, snoring, witnessed apneas, or hypertension) without complicating factors, requiring at least four hours of adequate data for validity. However, HSAT has limitations including lower sensitivity for mild , potential technical failures (up to 20% in some studies), and inability to rule out other sleep disorders, necessitating follow-up PSG if results are negative or inadequate despite persistent clinical suspicion. Alternative tests include devices like WatchPAT, a wrist-worn home monitor that assesses peripheral arterial tone (PAT) alongside actigraphy, oximetry, and heart rate to estimate sleep time and respiratory events without traditional airflow sensors. Validated against PSG, WatchPAT demonstrates good correlation for AHI estimation, making it suitable for uncomplicated OSAS diagnosis per AASM criteria for HSAT devices. Overnight oximetry trends provide a simpler screening option by tracking desaturation patterns to compute ODI, which correlates with OSAS severity but lacks specificity for confirming diagnosis without additional measures. These alternatives are particularly useful in resource-limited settings but should follow initial clinical screening tools for patient selection. Diagnosis of OSAS requires fulfillment of International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) criteria, mandating PSG or valid HSAT showing AHI ≥5 events per hour with associated symptoms (e.g., sleepiness, snoring, hypertension) or AHI ≥15 events per hour without symptoms. Severity is graded as mild (AHI 5–14), moderate (15–29), or severe (≥30), guiding management decisions. Split-night PSG, combining diagnostic and continuous positive airway pressure (CPAP) titration phases, is appropriate for patients likely to have severe OSAS, provided at least two hours of diagnostic data and three hours of titration are obtained.

Treatment and Management

Non-Invasive Therapies

Non-invasive therapies for obstructive sleep apnea syndrome (OSAS) form the cornerstone of initial management, emphasizing behavioral modifications and device-based interventions to improve airway patency without surgical intervention. These approaches target modifiable risk factors and provide symptomatic relief by reducing the frequency and severity of apneic events, as measured by the apnea-hypopnea index (AHI). Lifestyle changes often serve as first-line recommendations, particularly for patients with mild to moderate OSAS, while positive airway pressure devices and oral appliances offer more targeted mechanical support for broader efficacy across severity levels. Lifestyle modifications, including weight loss, positional therapy, and avoidance of alcohol, play a pivotal role in alleviating OSAS symptoms by addressing contributing factors such as obesity and supine positioning. Weight loss of 5-10% body weight has been shown to reduce AHI by approximately 25-26%, with even smaller reductions (<5%) decreasing respiratory events and greater losses (≥10%) potentially resolving severe cases in some patients. For instance, intensive lifestyle interventions leading to sustained weight reduction have demonstrated significant improvements in OSAS severity over long-term follow-up. Positional therapy, which discourages supine sleeping through wearable devices like vibrotactile sensors or positional pillows, effectively lowers AHI in patients with positional OSAS by promoting lateral positioning, with new-generation devices showing short-term reductions in supine time and overall apnea severity. Avoiding alcohol, especially within four hours of bedtime, is advised as it relaxes upper airway muscles, exacerbating collapse and increasing AHI; abstinence can mitigate these effects and improve overall sleep quality. Pharmacological treatments represent an emerging non-invasive option, particularly for patients with obesity-related OSAS. In December 2024, the U.S. Food and Drug Administration approved tirzepatide (Zepbound), a dual GLP-1 and GIP receptor agonist, as the first medication for moderate-to-severe OSAS in adults with obesity, to be used adjunctively with diet and exercise for chronic weight management, which can reduce AHI and improve symptoms. Clinical trials demonstrated significant AHI reductions proportional to weight loss achieved with the drug. Continuous positive airway pressure (CPAP) therapy remains the gold standard non-invasive device-based treatment, delivering a steady stream of pressurized air (typically 4-20 cmH₂O) via a mask to splint the upper airway open and normalize breathing patterns. CPAP effectively reduces AHI to near-normal levels in most patients and improves daytime sleepiness, cardiovascular outcomes, and quality of life. Mask options include nasal masks, which cover the nose for patients who breathe primarily through the nose, and full-face masks, which encompass both nose and mouth for mouth breathers or those with nasal congestion. Bilevel positive airway pressure (BiPAP) variants, providing higher inspiratory and lower expiratory pressures, are particularly useful for patients intolerant of CPAP due to high pressure requirements or respiratory comorbidities, offering comparable AHI reductions with potentially better comfort. However, adherence remains a challenge, with rates of consistent use (>4 hours/night) ranging from 50-70%, influenced by factors like mask fit, education, and symptom severity. Oral appliances, such as mandibular advancement splints (), represent an effective alternative for mild to moderate OSAS, protruding the lower forward by 5-10 mm to enlarge the pharyngeal airway and reduce collapsibility. These custom-fitted devices achieve at least a 50% AHI reduction in responsive patients, with higher success in positional or mild cases, and offer advantages in portability and adherence over CPAP. Monobloc and duobloc designs are common, with duobloc allowing greater customization and titration to optimize efficacy while minimizing side effects like temporomandibular discomfort. Myofunctional therapy involves targeted orofacial exercises to strengthen pharyngeal, , and facial muscles, enhancing airway stability and reducing and apneic events. Protocols typically include 30-minute daily sessions of maneuvers such as presses and elevations, leading to approximately 50% AHI reductions in adults when performed consistently over 3-6 months. This therapy is particularly beneficial as an adjunct or for patients intolerant to devices, improving and overall without invasive measures.

Surgical and Device-Based Interventions

Surgical and device-based interventions for syndrome (OSAS) are employed when non-invasive therapies, such as , fail or are poorly tolerated, targeting anatomical contributors to upper airway collapse. These approaches encompass surgeries, skeletal modifications, implantable devices, and minimally invasive techniques, with efficacy varying by patient selection, OSAS severity, and procedural specifics. Outcomes are typically measured by reductions in the apnea-hypopnea index (AHI), improvements in oxygenation, and alleviation of symptoms like daytime sleepiness. Uvulopalatopharyngoplasty (UPPP) involves excision of redundant , , and tonsillar tissues to enlarge the oropharyngeal airway and reduce collapsibility during . Introduced in the early 1980s, the procedure achieves success rates of 40-60% when defined as a ≥50% AHI reduction and postoperative AHI ≤20 events/hour, with higher efficacy in non-obese patients and those with retropalatal obstruction predominant on drug-induced . Mean AHI decreases by approximately 50%, though long-term relapse can occur due to unaddressed base-of-tongue collapse. In children, —frequently combined with —addresses OSAS driven by lymphoid , serving as a primary surgical option with minimal risks. Systematic reviews of over 1,000 pediatric cases report cure rates of 66%, defined variably as AHI <1 event/hour or per-study criteria, alongside significant overall AHI reductions from baseline levels. Success exceeds 80% in non-obese children without comorbidities, though residual OSAS persists in up to 40% of cases involving or craniofacial anomalies. Tracheostomy offers a definitive for severe, life-threatening OSAS to other interventions, creating a direct airway below the site of obstruction. Meta-analyses confirm near-universal , with AHI reductions exceeding 90% (from means of 92 to 17 events/hour) and parallel improvements in oxygen desaturation index, scores, and cardiovascular mortality. Reserved for cases with cor pulmonale, , or CPAP intolerance, it carries risks of and speech alterations but remains a salvage with sustained benefits. Hypoglossal nerve stimulation, exemplified by the Inspire therapy system, involves implantation of a pacemaker-like device that delivers unilateral electrical pulses to protrude the and counteract hypopharyngeal during sensed inspiratory efforts. FDA-approved in 2014 for moderate-to-severe OSAS (AHI 15-65 events/hour) in CPAP-intolerant adults with BMI ≤32 kg/m², pivotal trials like the STAR study reported a 68% AHI reduction at 12 months, with 66% of participants achieving AHI <10 events/hour and over 50% responder rate sustained at 36 months. Patient activation via remote control enhances tolerability, though eligibility requires absence of complete concentric on . Maxillomandibular advancement (MMA) constitutes a multilevel advancing the upper and lower jaws to expand the skeletal framework and pharyngeal airspace by up to 10-15 mm. Indicated for craniofacial anomalies or multilevel collapse unresponsive to softer interventions, long-term follow-up of over 100 patients demonstrates an 83% success rate (AHI ≤15 events/hour with resolved sleepiness), with mean AHI dropping from 49 to 11 events/hour over 6+ years. Benefits extend to lowered and enhanced quality-of-life scores, despite transient sensory neuropathies in 20-30% of cases. Emerging options like (somnoplasty) employ low-energy thermal coagulation to volumetrically reduce and stiffen vibratory tissues in the or tongue base, suitable as an office-based procedure for mild-to-moderate OSAS. Clinical series indicate AHI reductions of 45-50% (from means of 16 to 8 events/hour) at 3-6 months, with 30% achieving curative AHI <5 events/hour, particularly among those with baseline AHI <15 and lower . Complications are rare (e.g., transient ulceration in <10%), positioning it as a low-morbidity , though durability wanes beyond 2 years in some cohorts.

Complications and Prognosis

Associated Health Risks

Untreated obstructive sleep apnea syndrome (OSAS) is associated with a range of multi-system health risks, primarily due to recurrent episodes of , sleep fragmentation, and sympathetic activation. These complications span cardiovascular, metabolic, neurological, and other domains, contributing to increased morbidity and mortality if left unmanaged. In the cardiovascular system, OSAS significantly elevates the risk of , affecting approximately 50% of patients with the condition. It also increases the likelihood of by 2- to 3-fold, by about 2-fold, and by up to 140%. These risks arise from intermittent and , which promote and . Additionally, OSAS contributes to through chronic and pulmonary . Metabolically, OSAS promotes through hypoxia-induced mechanisms, thereby raising the risk of independent of . It is also linked to , characterized by elevated triglycerides and reduced levels, which further exacerbates cardiometabolic disease. These effects stem from disrupted glucose and during apneic episodes. Neurologically, OSAS contributes to cognitive decline and increases risk, particularly in severe cases where the odds may rise up to 3-fold compared to non-apneic individuals. Daytime sleepiness from OSAS also heightens the risk of accidents by 2- to 7-fold. These impairments result from chronic sleep disruption and affecting memory and attention. Other risks include nonalcoholic fatty liver disease (), where OSAS accelerates hepatic fat accumulation via , , and . In children, OSAS can mimic attention-deficit/hyperactivity disorder (ADHD) symptoms, such as inattention and hyperactivity, leading to potential misdiagnosis; up to 25% of pediatric ADHD cases may involve undiagnosed OSAS.

Treatment Outcomes and Mortality

Untreated (OSAS) significantly elevates mortality risk, particularly from cardiovascular causes. Patients with severe untreated OSAS face a 3-fold increased risk of fatal cardiovascular events compared to those with milder or treated forms. Longitudinal studies, including analyses, demonstrate that severe untreated cases exhibit a marked decline in 10-year rates, with excess mortality driven largely by cardiovascular complications such as and . For instance, in a prospective of patients with / syndrome, untreated severe OSAS was linked to higher all-cause mortality, as evidenced by Kaplan-Meier curves showing divergence from treated groups within the first decade. Effective treatment of OSAS, particularly with (CPAP), yields substantial improvements in prognosis and . Adherent CPAP use reduces risk by 30-50% in patients with moderate to severe OSAS, based on meta-analyses of clinical trials demonstrating lowered incidence of cerebrovascular events with consistent therapy. Additionally, CPAP enhances health-related , with scores improving by 10-20 points across domains such as vitality and physical functioning after several months of treatment, reflecting reduced daytime sleepiness and better overall well-being. These benefits extend to cardiovascular survival, where long-term CPAP adherence mitigates the seen in untreated cohorts, potentially lowering all-cause death risk by up to 37%. However, treatment outcomes are tempered by adherence challenges, which affect up to 50% of patients. Dropout rates for CPAP therapy range from 30-60% within the first year, with predictors including , which doubles the likelihood of non-adherence due to discomfort from the mask interface. Other factors, such as low initial usage and psychological barriers like anxiety, further contribute to suboptimal compliance, limiting the realization of survival benefits. Interventions targeting these predictors, such as behavioral support, can improve long-term adherence and associated outcomes. Regarding neurocognitive reversal, OSAS treatment offers promising but variable recovery. CPAP therapy leads to noticeable improvements in , such as and verbal fluency, often within the first few months, with studies reporting partial restoration of cognitive performance and brain electrophysiology after six months of use. In long-standing cases, however, reversal may be incomplete, as chronic can cause persistent structural changes in regions like the , limiting full neurocognitive recovery despite sustained treatment. These findings underscore the importance of early intervention to maximize prognostic benefits.

Epidemiology and Public Health

Prevalence and Demographics

Obstructive sleep apnea syndrome (OSAS) has a substantial global , with estimates indicating that 9% to 38% of adults are affected when defined by an apnea-hypopnea index (AHI) of ≥5 events per hour, based on recent meta-analyses of epidemiological studies. In children, the prevalence is considerably lower, ranging from 1% to 6%, often peaking between ages 2 and 8 years and primarily linked to adenotonsillar hypertrophy. Within the , OSAS impacts approximately 80 million adults as of 2025, reflecting the condition's widespread occurrence amid rising rates. Demographic patterns reveal OSAS to be more common in men, with a male-to-female ratio of 2:1 to 3:1 in community-based populations, though this disparity narrows in clinical settings for milder cases. The condition's increases with age, typically peaking between 40 and 60 years, after which severity may plateau or decline in older adults despite higher overall rates. serves as a key correlate, present in approximately 70% of OSAS cases, underscoring the mechanical role of excess in airway obstruction. Ethnic variations further influence OSAS distribution, with moderate-to-severe cases (AHI ≥15) showing higher prevalence among (around 13%) compared to Caucasians (4% to 5%), as evidenced by population studies like the Sleep Heart Health Study adjusting for age and . Despite these estimates, OSAS remains significantly underdiagnosed, with only 10% to 20% of cases identified in affected populations, though diagnostic rates have begun to rise following heightened awareness efforts since 2020.

Global Burden and Underdiagnosis

Obstructive sleep apnea syndrome (OSAS) imposes a substantial burden, affecting an estimated 936 million adults aged 30–69 years worldwide with mild to severe disease, including 425 million with moderate-to-severe cases. Projections indicate that by 2050, this could rise to over 1 billion globally, driven by aging populations and trends. In the United States, the annual economic cost of undiagnosed OSAS exceeds $150 billion, encompassing direct medical expenses, losses, and accident-related expenditures. This includes approximately $86.9 billion in lost due to presenteeism and absenteeism, $26.2 billion from motor vehicle accidents, and $6.5 billion from workplace incidents, highlighting the disorder's impact on workforce efficiency and safety. Globally, untreated OSAS contributes to heightened healthcare utilization, with costs per patient reaching up to €28,000 annually in some regions, underscoring the need for broader economic modeling to address its societal toll. Underdiagnosis of OSAS remains a critical challenge, with rates exceeding 80% in many populations, driven by multiple barriers to detection. Key factors include limited access to diagnostic services in low-income and rural regions, where socioeconomic constraints and geographic isolation hinder evaluation. Additionally, surrounding disorders often leads patients to dismiss symptoms like or as benign, compounded by a lack of routine screening in settings due to provider challenges and low confidence in identifying at-risk individuals. These systemic issues perpetuate delayed diagnosis, exacerbating associated comorbidities and economic strain. Public health efforts aim to mitigate this burden through targeted initiatives, including the (AASM) guidelines recommending annual screening for adults with risk factors such as , , or elevated using validated tools and the HEARTS criteria (, Elevated blood pressure, , Resistant , , ). The has increasingly linked OSAS to non-communicable diseases, advocating for its integration into broader chronic disease management frameworks to improve recognition and resource allocation. Since 2025, advancements in telemedicine have begun addressing diagnostic gaps, enabling remote home testing and virtual consultations that enhance accessibility, particularly in underserved areas. The Respiratory Society's 2025 statement endorses telemedicine across OSAS and stages, with studies showing improved engagement and earlier intervention through structured remote support. These innovations, including AI-assisted screening pathways, are projected to reduce underdiagnosis disparities by facilitating scalable, cost-effective evaluations.

History and Research Directions

Historical Recognition

The earliest descriptions of symptoms resembling obstructive sleep apnea syndrome (OSAS) trace back to literary and medical observations linking to and respiratory issues. In 1837, depicted a character in The Posthumous Papers of the Pickwick Club exhibiting profound and , inspiring later . Sir first explicitly connected to this "Pickwickian" presentation in 1918, describing it as a syndrome of and in obese individuals. The modern clinical recognition came in 1956 with a seminal by Burwell et al., who formalized "Pickwickian syndrome" as extreme associated with alveolar , , and , though without specific emphasis on sleep-related apneas. Recognition of sleep-specific apneas emerged in the , shifting focus from wakeful to nocturnal events. In , Gastaut et al. produced the first polysomnographic recording demonstrating recurrent apneas during in patients with , establishing OSAS as a distinct sleep-disordered entity rather than solely an obesity-related condition. This period marked growing awareness that apneas were not universal in obese patients but tied to upper airway collapse during , with early reports from European researchers highlighting , witnessed apneas, and daytime fatigue as core features. The 1970s advanced diagnostic capabilities through the development of polysomnography by William Dement and colleagues at Stanford University, who established the first sleep clinic in 1970 and coined the term "polysomnography" to integrate EEG, respiratory, and other monitoring for objective sleep analysis. This tool enabled precise quantification of apneic events, leading to the identification of the apnea-hypopnea index (AHI) as a key metric. In the 1980s, treatment milestones included Colin Sullivan's invention of continuous positive airway pressure (CPAP) in 1980, first tested on a patient in 1981, which non-invasively maintained airway patency and reversed apneas, transforming OSAS management. From the 1990s to the 2000s, OSAS understanding evolved with standardized classifications and epidemiological links. The (ICSD) was first published in 1990 by the American Sleep Disorders Association, categorizing OSAS under sleep-related breathing disorders and distinguishing adult from pediatric forms based on AHI thresholds and symptoms. Revisions in 1997 and the ICSD-2 in 2005 refined criteria, incorporating evidence of cardiovascular risks and emphasizing OSAS's role in the rising epidemic, with prevalence studies showing strong associations between and apnea severity. Pediatric OSAS received limited attention before 2000, often conflated with adenotonsillar hypertrophy rather than as a , but post-2000 research expanded recognition of its neurocognitive impacts in children. A notable advancement came in 2014 with FDA approval of the Inspire Upper Airway Stimulation system, the first stimulator for moderate-to-severe OSAS in CPAP-intolerant adults, marking a shift toward implantable therapies.

Emerging Therapies and Studies

Recent clinical trials have advanced pharmacotherapy for obstructive sleep apnea syndrome (OSAS), with AD109, a combination of aroxybutynin and atomoxetine targeting upper airway muscle tone and arousal threshold, demonstrating significant efficacy. In the 2025 SynAIRgy phase 3 trial, AD109 achieved a statistically significant reduction in the apnea-hypopnea index (AHI), with 51.2% of participants showing a decrease in OSAS severity category compared to placebo. Similarly, the LunAIRo phase 3 trial reported that 45% of treated patients experienced improved disease severity at week 26, marking a potential first oral therapy for moderate-to-severe OSAS. Apnimed plans to submit a New Drug Application to the FDA in early 2026. Device-based interventions have also seen expansions, particularly with stimulation therapies like Inspire. In 2023, the FDA approved an increase in the upper limit for Inspire to 40 kg/m² from 32 kg/m², enabling treatment for a broader population including those with greater than 35. By 2024, the Inspire V system received further approval, maintaining this expanded indication while confirming durable AHI reductions of over 60% at five years post-implantation in eligible s. coverage now aligns with up to 35 kg/m² for many cases, improving access. Emerging research explores to enhance pharyngeal muscle tone, addressing core pathophysiological deficits in OSAS. A 2020 preclinical study in mice demonstrated that targeted to hypoglossal motor neurons prevented airway collapse during sleep, reducing obstructive events. These efforts highlight gene therapy's potential as a one-time intervention, though human trials remain in early stages. Artificial intelligence (AI) is optimizing continuous positive airway pressure (CPAP) therapy through real-time adjustments and . A 2025 study outlined AI algorithms that analyze breathing patterns to dynamically modulate pressure, improving adherence and efficacy in OSAS patients. Studies from 2024-2025 also integrate AI with wearable oximetry for automated CPAP , reducing residual AHI by up to 20% in non-compliant users. Additionally, training, such as playing, has shown benefits in strengthening upper airway muscles; a 2006 randomized trial confirmed approximately 50% AHI drops with consistent practice, while a 2024 assessed its practicality in small cohorts. Updated epidemiological data from projections based on NHANES trends indicate a rising OSAS burden, with expected to increase by about 5% relative to prior estimates by 2025, driven by aging populations and . A 2025 analysis projected a 34.7% overall rise in OSAS cases to 77 million U.S. adults by 2050, with women experiencing a 65% relative increase. Longitudinal studies from 2024-2025 have linked long-COVID to heightened OSAS risk, with post-acute sequelae of (PASC) patients showing 2.6 times higher odds of new-onset sleep-disordered breathing due to persistent inflammation and autonomic dysfunction. One 2025 found incident OSAS in 25% of primary survivors followed for 12 months. Future directions emphasize wearable technologies for real-time OSAS monitoring and genomics-driven . Wearables equipped with and biosensors enable continuous tracking of respiratory events and oxygen desaturation, facilitating early intervention and therapy adjustments outside clinical settings. In personalized approaches, genomic profiling identifies endotypes—such as collapsibility or traits—guiding tailored interventions like targeted or surgery. A 2023 framework proposed using genetic and phenotypic data to stratify OSAS subtypes, potentially improving outcomes by 30-50% over one-size-fits-all treatments. Ongoing trials integrate these elements to address underdiagnosis and risks.

References

  1. [1]
    Obstructive Sleep Apnea - StatPearls - NCBI Bookshelf
    Mar 4, 2025 · Obstructive sleep apnea (OSA) is a sleep disorder characterized by repeated episodes of complete (apnea) or partial (hypopnea) collapse of the upper airway.Obstructive Sleep Apnea · Evaluation · Treatment / Management
  2. [2]
    Obstructive sleep apnea - Symptoms and causes - Mayo Clinic
    Jul 14, 2023 · Obstructive sleep apnea is the most common sleep-related breathing disorder. People with obstructive sleep apnea repeatedly stop and start ...
  3. [3]
    Obstructive Sleep Apnea (OSA): Symptoms & Treatment
    Obstructive Sleep Apnea. Obstructive sleep apnea (OSA) is when you stop breathing during sleep because of a blockage in your windpipe.
  4. [4]
    [PDF] Obstructive Sleep Apnea
    Obstructive sleep apnea (OSA) is a sleep-related breathing disorder that involves a decrease or complete halt in airflow despite an ongoing effort to ...Missing: abbreviation | Show results with:abbreviation
  5. [5]
    Apnea - Etymology, Origin & Meaning
    Apnoea, from Greek apnoia meaning "absence of respiration," combines a- "without" + pnein "to breathe"; originally and commonly denotes suspension of ...
  6. [6]
    Syndrome - Etymology, Origin & Meaning
    Originating from Greek syndrome meaning "concurrence of symptoms," syndrome refers to a number of symptoms occurring together, derived from syn- "with" + ...
  7. [7]
    Central sleep apnea - Symptoms and causes - Mayo Clinic
    Jul 29, 2025 · This condition is different from obstructive sleep apnea, in which breathing stops because the throat muscles relax and block the airway. ...
  8. [8]
    Sleep apnea - Symptoms and causes - Mayo Clinic
    Apr 6, 2023 · Sleep apnea is a potentially serious sleep disorder in which breathing repeatedly stops and starts. If you snore loudly and feel tired even after a full night' ...Polysomnography (sleep study) · Diagnosis and treatment · CPAP: How it works<|control11|><|separator|>
  9. [9]
    [PDF] ICSD-3-TR
    1. One or more obstructive apneas, mixed apneas, or hypopneas per hour of sleep. 2. A pattern of obstructive hypoventilation, defined as at least 25% of total ...
  10. [10]
    [PDF] Clinical Practice Guideline for Diagnostic Testing for Adult ...
    The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-deter- mined obstructive respiratory disturbance index ( ...
  11. [11]
    Pediatric Obstructive Sleep Apnea - StatPearls - NCBI Bookshelf - NIH
    Pediatric obstructive sleep apnea (OSA) is a childhood disorder in which there is upper airway dysfunction causing complete or partial airway obstruction ...
  12. [12]
    Understanding Pediatric Positional Obstructive Sleep Apnea
    Oct 3, 2024 · This study investigates the prevalence, risk factors, and clinical characteristics of positional obstructive sleep apnea (POSA) among pediatric patients<|control11|><|separator|>
  13. [13]
    Evaluation and Management of Obesity Hypoventilation Syndrome ...
    The purpose of this guideline is to optimize evaluation and management of patients with obesity hypoventilation syndrome (OHS).
  14. [14]
    American Academy of Sleep Medicine Position Paper for the Use of ...
    Oct 15, 2017 · The International Classification of Sleep Disorders, Third Edition (ICSD-3) defines pediatric OSA as an AHI ≥ 1 or a pattern of obstructive ...ABSTRACT · INTRODUCTION · BACKGROUND · POSITION STATEMENT
  15. [15]
    Polysomnography for Obstructive Sleep Apnea Should Include ...
    Per the AASM International Classification of Sleep Disorders (ICSD-3), diagnostic criteria for adults include either having (1) five or more predominantly ...
  16. [16]
    Adult Obstructive Sleep Apnea: Pathophysiology and Diagnosis - PMC
    Obstructive sleep apnea (OSA) is a highly prevalent disease characterized by recurrent episodes of upper airway obstruction that result in recurrent arousals.
  17. [17]
    Nocturia in Women With Obstructive Sleep Apnea - PMC
    Jun 18, 2018 · Nocturia is defined as waking up from sleep 2 times or more to void and is a common symptom in patients with obstructive sleep apnea (OSA).
  18. [18]
    Daytime sleepiness, snoring, and obstructive sleep apnea ... - PubMed
    The Epworth Sleepiness Scale (ESS) is a simple questionnaire measuring the general level of daytime sleepiness, called here the average sleep propensity.
  19. [19]
    Obstructive Sleep Apnea is Linked to Depression and Cognitive ...
    There is strong evidence that patients with untreated moderate to severe OSA have increased rates of depression, cognitive impairment, and dementia.
  20. [20]
    Cognitive Impairment and Affective Disorders in Patients With ...
    Patients with obstructive sleep apnea experience neuropsychological symptoms such as anxiety, attention deficits, cognitive impairment, depressive symptoms.Missing: mood | Show results with:mood
  21. [21]
    Gender Issues in Obstructive Sleep Apnea - PMC - PubMed Central
    Sep 30, 2021 · Women are more likely to report non-specific symptoms of OSA, such as mood disturbance, lack of energy, daytime fatigue, morning headache, ...
  22. [22]
    Gender differences in obstructive sleep apnea syndrome - PubMed
    Fatigue, morning headaches, insomnia, depression and use of sedatives were more frequent in women than in men. Women were older than men, more obese (although ...
  23. [23]
    The influence of gender on symptoms associated with obstructive ...
    Conclusion: Women with OSA were more likely to report tiredness, initial insomnia, and morning headaches, and less likely to complain of typical OSA symptoms ( ...
  24. [24]
    Obstructive Sleep Apnea and Hypertension: A Review of the ... - NIH
    OSA and hypertension share many common factors in pathophysiology, such as gender, obesity, unhealthy lifestyle, impaired quality of sleep, renin-angiotensin ...
  25. [25]
    Obstructive sleep apnea, hypertension, and obesity: A dangerous triad
    Sep 18, 2019 · Obesity and OSA tend to coexist and they are associated with inflammation, insulin resistance, dyslipidemia, and high blood pressure (BP), but the causal ...
  26. [26]
    Learning About Sleep Apnea in Children | Kaiser Permanente
    Children who have sleep apnea nearly always snore. But unlike adults with sleep apnea, they may not seem very sleepy during the day. In younger children, other ...
  27. [27]
    Obstructive Sleep Apnea in Children - AAFP
    Mar 1, 2004 · Consequences of untreated obstructive sleep apnea include failure to thrive, enuresis, attention-deficit disorder, behavior problems, poor ...
  28. [28]
    Obstructive Sleep Apnea in Children - Cleveland Clinic
    Childhood sleep apnea is a condition in which there are brief pauses in your child's breathing pattern during sleep.
  29. [29]
    Understanding the Anatomic Basis for Obstructive Sleep Apnea ...
    In adults, there are known anatomic risk factors for OSAS, including enlargement of the tongue, soft palate, parapharyngeal fat pads, and lateral pharyngeal ...
  30. [30]
    Sleep apnoea in older people | European Respiratory Society
    OSA occurs due to a loss of pharyngeal dilator muscle tone and increased ... Another factor that may predispose older people to sleep apnoea is the age-related ...
  31. [31]
    Female sex hormones and symptoms of obstructive sleep apnea in ...
    Jun 22, 2022 · The prevalence of obstructive sleep apnea is higher in women after menopause. This is suggested to be a result of an altered sex hormone ...
  32. [32]
    Alcohol and the risk of sleep apnoea: a systematic review and meta ...
    Alcohol consumption increased the risk of sleep apnoea by 25%. · Findings were robust to differences in definitions of alcohol consumption and sleep apnoea.
  33. [33]
    The genetics of obstructive sleep apnea - PMC - PubMed Central - NIH
    Obstructive sleep apnea (OSA) is a genetically complex disease that likely results from multiple interacting genetic and environmental factors.
  34. [34]
    Association of tumor necrosis factor-α-308G/A polymorphism with ...
    Aug 18, 2023 · This meta-analysis suggested that TNF-α-308A allele may be a risk factor for the development of OSA. However, large scale,multi-center and well-designed case- ...Missing: familial predisposition
  35. [35]
    Mayo Clinic Q and A: Neck size one risk factor for obstructive sleep ...
    Jun 20, 2015 · A neck size greater than 16 or 17 inches is a sign of excess fat in the neck area. This may contribute to crowding and narrowing of your breathing tube.Missing: lifestyle supine position
  36. [36]
    Where There Is Smoke…There Is Sleep Apnea - PubMed Central
    Cigarette smoking may increase the severity of OSA through alterations in sleep architecture, upper airway neuromuscular function, arousal mechanisms, and upper ...
  37. [37]
    Obstructive Sleep Apnea | Circulation
    Aug 11, 2015 · Sleeping supine (on the back), Sleep in the lateral (side) or prone (stomach) position. Expand Table. OSA indicates obstructive sleep apnea. *.
  38. [38]
    Disparities and Genetic Risk Factors in Obstructive Sleep Apnea - NIH
    Craniofacial structure among Asians appears to confer an elevated risk of OSA despite lower rates of obesity. Among African Americans, Native Americans, and ...
  39. [39]
    Hypoxia-inducible factors and obstructive sleep apnea - PMC
    Interruption of breathing by OSA results in intermittent hypoxia (IH), mild hypercapnia, and arousals from sleep.Chemoreflex Activation By Ih... · Figure 1. Schematic... · Long-Term Ih Activates...
  40. [40]
    Obstructive sleep apnea: the new cardiovascular disease. Part I
    Patients with OSA experience recurrent episodes of sympathetic activation and blood pressure surges throughout the sleep period [20].Missing: architecture | Show results with:architecture
  41. [41]
    Slow-wave sleep, oxygen desaturation, and memory consolidation ...
    May 6, 2025 · OSA is characterized by intermittent hypoxia, sleep fragmentation, and reductions in SWS and rapid eye movement (REM) sleep.
  42. [42]
    Sleep apnoea and the heart - PMC - PubMed Central - NIH
    Intermittent hypoxia is associated with sympathetic nervous system overactivity, systemic inflammation and oxidative stress leading to endothelial dysfunction ...
  43. [43]
    Chronic intermittent hypoxia and obstructive sleep apnea
    Notes: During OSA, intermittent cycles of a fall in oxygen saturation and reoxygenation, and a rise in UA and esophageal pressure, MA, and hypercapnia occur.
  44. [44]
    Metabolic dysfunction in obstructive sleep apnea - PMC - NIH
    Oxidative stress further worsens insulin resistance and in turn, metabolic dysfunction also increases oxidative stress. However, despite many studies ...
  45. [45]
    Atrial Arrhythmias in Obstructive Sleep Apnea - NIH
    Mar 12, 2013 · Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm. 2011;(9 ...
  46. [46]
    Relationship Between Arrhythmia and Sleep Disordered Breathing
    Many studies have shown increased arrhythmia prevalence and incidence, including atrial fibrillation, in patients with OSA compared to patients without sleep ...
  47. [47]
    Hormonal and metabolic profiles in subjects with obstructive sleep ...
    Nocturnal secretion of growth hormone is impaired in patients with obstructive sleep apnea (OSA), but the metabolic consequences have not been reported.Missing: elevated | Show results with:elevated
  48. [48]
    Clinical Practice Guideline for Diagnostic Testing for Adult ...
    The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index ...
  49. [49]
    New Method for Measuring Daytime Sleepiness: The Epworth ...
    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire measuring daytime sleepiness by rating chances of dozing in eight daily situations.
  50. [50]
    Validation study of portable device for the diagnosis of obstructive ...
    Abstract. Conclusion: Watch-PAT may provide an accurate and clinically effective portable monitoring method for the diagnosis of obstructive sleep apnea (OSA).
  51. [51]
    Overnight pulse oximetry for obstructive sleep apnea screening ...
    A study conducted in primary care of Hong Kong concludes that overnight pulse oximetry is a good screening tool for OSA screening.
  52. [52]
  53. [53]
    Approach the Patient With Obstructive Sleep Apnea and Obesity
    Conversely, a 10% weight loss predicted a 26% decrease in the AHI (6). Obesity contributes to OSA by the accumulation of adipose tissue around the pharyngeal ...
  54. [54]
    Dose-response relationship between weight loss and improvements ...
    Even a < 5% weight loss can reduce respiratory events, but a ≥ 5% and ideally ≥ 10% weight loss is necessary for reducing the prevalence of severe OSA. Clinical ...ABSTRACT · METHODS · RESULTS · DISCUSSION
  55. [55]
    Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention ...
    Apr 22, 2022 · An 8-week interdisciplinary weight loss and lifestyle intervention significantly improved OSA severity and other outcomes compared with usual care alone.
  56. [56]
    Efficacy of the New Generation of Devices for Positional Therapy for ...
    There is strong evidence that the new generation of devices for PT are effective in reducing the apnea-hypopnea index during short-term follow-up.
  57. [57]
    Efficacy of vibrotactile positional therapy devices on patients with ...
    Vibrotactile positional therapy was effective in reducing time spent in the supine position and the severity of OSA, plus daytime sleepiness; however, this ...
  58. [58]
    Obstructive sleep apnea - Diagnosis and treatment - Mayo Clinic
    Jul 14, 2023 · Learn the signs that point to this common and potentially serious sleep disorder. And find out the treatments that can help you sleep ...
  59. [59]
    Obstructive sleep apnea: Overview of management in adults
    Sep 17, 2025 · Outline · SUMMARY AND RECOMMENDATIONS · INTRODUCTION · GENERAL ISSUES FOR ALL PATIENTS · Supportive care · POSITIVE AIRWAY PRESSURE (PAP) THERAPY.
  60. [60]
    CPAP Pressure Settings - SleepApnea.org
    Aug 4, 2025 · A CPAP's pressure level is a numeric value measured in centimeters of water (cm H2O). Many CPAP machines can operate at pressures ranging from 4 to 20 cm H2O.
  61. [61]
    Which CPAP masks are best for you? - Mayo Clinic
    Many CPAP mask options available · Nasal pillow mask · Nasal masks · Full-face masks, also called oronasal masks · Oral mask, known as a hybrid mask.
  62. [62]
    Treatment of Adult Obstructive Sleep Apnea With Positive Airway ...
    OSA Severity. The efficacy of BPAP compared to CPAP in reducing OSA severity in adults with OSA was evaluated in a meta-analysis of 2 RCTs.
  63. [63]
    Long term adherence to continuous positive Airway pressure in mild ...
    Sep 1, 2023 · Observational studies suggest adherence(compliance) with CPAP therapy is between 30 to 60% [5]. In mild OSA, in which treatable symptoms are ...
  64. [64]
    Oral appliances in the treatment of obstructive sleep apnea in adults
    Jul 15, 2025 · Mandibular advancement splint (MAS) therapy appears to consistently improve indices of OSA including the apnea-hypopnea index (AHI), although ...
  65. [65]
    An update on mandibular advancement devices for the treatment of ...
    Complete resolution of OSAHS: AHI <5; partial resolution: ≥50% reduction in AHI. OSAHS, obstructive sleep apnoea hypopnoea syndrome; AHI, apnoea-hypopnoea index ...Introduction · Efficacy of MAD · Design features influencing... · Side effects of MAD<|control11|><|separator|>
  66. [66]
    The Efficacy of Various Orthodontic Appliances in the Treatment of ...
    Both monobloc and bibloc devices have been shown to be effective in cases of moderate OSA, while in cases of more severe forms of OSA, bibloc devices showed ...
  67. [67]
    Myofunctional Therapy to Treat Obstructive Sleep Apnea - NIH
    Current literature demonstrates that myofunctional therapy decreases apnea-hypopnea index by approximately 50% in adults and 62% in children.
  68. [68]
    Orofacial Myofunctional Therapy for Obstructive Sleep Apnea
    Conclusion: OMT may provide a reasonable alternative for OSA patients who cannot tolerate CPAP or other more established treatment options. OMT benefits appear ...
  69. [69]
    Uvulopalatopharyngoplasty in the Management of Obstructive Sleep ...
    The reported success of UPPP as a treatment of OSA is between 16% and 83%, depending on the definition of a positive outcome. Some authors have defined surgical ...
  70. [70]
    Updated systematic review of tonsillectomy and adenoidectomy for ...
    Random-effects model estimated the treatment success of T&A was 66.3 percent, when cure was defined per each individual study. When "cure" was defined as an ...
  71. [71]
    Tracheostomy as treatment for adult obstructive sleep apnea - PubMed
    Tracheostomies significantly decrease apnea index, oxygen desaturation index, sleepiness, and mortality in OSA subjects.
  72. [72]
    Insights since FDA Approval of Hypoglossal Nerve Stimulation for ...
    The Inspire-sponsored FDA Phase III Stimulation Therapy for Apnea Reduction (the STAR trial) has to date the most information on outcomes with this therapy: ...
  73. [73]
    Long-Term Effectiveness and Safety of Maxillomandibular ...
    MMA is a clinically effective and safe long-term treatment for most patients with moderate-to-severe OSA as demonstrated by significant decreases in AHI, ...
  74. [74]
    Factors Associated with Successful Treatment by Radiofrequency ...
    Radiofrequency ablation (RFA) treatment is effective to reduce snoring and also sleepiness symptoms [7]. The procedure can be performed in the ambulatory ...
  75. [75]
    Obstructive Sleep Apnea and Cardiovascular Disease: Role of the ...
    Obstructive sleep apnea increases the risk of heart failure by 140%, the risk of stroke by 60%, and the risk of coronary heart disease by 30%. Thus, sleep apnea ...
  76. [76]
    Obstructive Sleep Apnea and Hypertension – an Update - PMC
    Obstructive sleep apnea (OSA) is highly relevant to patients with hypertension (HTN): These two conditions frequently co-exist (an estimated 50% of patients ...
  77. [77]
    Sleep Disordered Breathing and Cardiovascular Disease - JACC
    Patients with untreated OSA followed over 4 years have a 2- to 3-fold increased risk ... Independent association between obstructive sleep apnea and subclinical ...
  78. [78]
    Obstructive Sleep Apnea and Cardiovascular Disease
    Jun 21, 2021 · Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea.Risk Factors · Atrial Fibrillation · Heart Failure
  79. [79]
    You Cannot Hit Snooze on OSA: Sequelae of Pediatric Obstructive ...
    Untreated or inadequately treated OSA in children can lead to systemic and pulmonary hypertension, postural orthostatic hypertension syndrome, cardiac ...
  80. [80]
    Obstructive Sleep Apnea: Role in the Risk and Severity of Diabetes
    Current evidence supports a robust association between OSA and insulin resistance, glucose intolerance and the risk of type 2 diabetes, independent of obesity.
  81. [81]
    Metabolic Consequences of Obstructive Sleep Apnea Especially ...
    Apr 15, 2019 · A possible mechanism linking OSA causally to T2DM is intermittent hypoxia which may provoke β-cell dysfunction and insulin resistance [22]. An ...DIAGNOSIS OF... · EPIDEMIOLOGY OF OSA AND... · PHYSIOLOGIC...
  82. [82]
    Obstructive sleep apnea and dyslipidemia: evidence and underlying ...
    The aim of this review is to highlight the relationship between OSA and dyslipidemia in the development of atherosclerosis and present the pathophysiologic ...
  83. [83]
    Obstructive Sleep Apnea: A Cardiometabolic Risk in Obesity and the ...
    OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis.<|control11|><|separator|>
  84. [84]
    The relationship between Obstructive Sleep Apnea and Alzheimer's ...
    First, in a prospectively longitudinal study, 105 elderly women with OSA had a higher risk of developing mild cognitive impairment (MCI) or dementia compared ...
  85. [85]
    Motor vehicle accidents in CPAP-compliant obstructive sleep apnea ...
    Feb 14, 2020 · Obstructive sleep apnea (OSA) has been associated with a 2–7-fold risk of motor vehicle accidents (MVAs) [1]. Body mass index (BMI) ...
  86. [86]
    Obstructive sleep apnea syndrome and fatty liver - NIH
    Obstructive sleep apnea can induce non-alcoholic fatty liver disease through increasing insulin resistance, dyslipidemia and inflammation. The presence of ...
  87. [87]
    Pediatric Obstructive Sleep Apnea (OSA) & ADHD Link
    Sep 19, 2021 · Research has shown that children with SDB, particularly OSA, display ADHD symptoms more often than those without SDB symptoms [10]. ADHD is ...
  88. [88]
    Mortality in severe sleep apnoea/hypopnoea syndrome patients
    The aim of this study was to determine mortality in patients with sleep apnoea/hypopnoea syndrome (SAHS) according to the treatments employed and comorbidity.
  89. [89]
    Continuous positive airway pressure with good adherence can ...
    Jul 15, 2020 · The meta-analysis suggests that CPAP therapy may reduce the risk of stroke in patients with good adherence and patients with moderate to severe OSA.
  90. [90]
    Comparative Study of Autotitrating and Fixed-Pressure CPAP in the ...
    Power analysis calcula- tions showed that 52 subjects were required to demonstrate a change in 2 points in Epworth Sleepiness Score or 10 points in. SF-36 ...
  91. [91]
    CPAP Therapy Reduces Risk of All‐Cause and Cardiovascular ...
    Mar 28, 2025 · The study findings showed positive results. Patients using CPAP had a 37% reduced risk of dying from any cause compared to non-CPAP users ( ...
  92. [92]
    [PDF] A Brief Review of Claustrophobia and Continuous Positive Airway ...
    Mar 22, 2016 · CPAP adherence rates have been estimated to range between 30-60%. [5]. Reasons for non-adherence to CPAP are varied and complex, and may include ...
  93. [93]
    Claustrophobic Tendencies and Continuous Positive Airway ...
    Aug 6, 2025 · Claustrophobic subjects were twice likely to be non-adherent to CPAP as compared to those without claustrophobia. ...
  94. [94]
    Neurocognitive Performance Improvement after Obstructive Sleep ...
    Dec 16, 2021 · Conclusions: CPAP treatment seems to improve cognitive defects associated with OSA. Limited studies have evaluated the effects of the other ...
  95. [95]
    Improvements in cognitive function and quantitative sleep ...
    Jan 13, 2022 · These findings suggest the reversibility of cognitive deficits and altered brain electrophysiology observed in untreated OSA following six ...
  96. [96]
    Obstructive Sleep Apnea: Brain Structural Changes and ...
    May 4, 2010 · This can be reversed by treatment with an increase of gray-matter volume in specific hippocampal and frontal brain regions. These changes are ...
  97. [97]
    The Global Burden of Obstructive Sleep Apnea - PMC
    Apr 25, 2025 · Recent meta-analyses estimate the prevalence of OSA in adults to range from 9% to 38%, depending on the diagnostic criteria applied [24].
  98. [98]
    Obstructive Sleep Apnea (OSA) in Children - DynaMed
    Aug 28, 2024 · The reported prevalence of OSA in children ranges from 1% to 6%, and it peaks between ages 2-8 years. · Among children with a risk factor for OSA ...
  99. [99]
    Rising prevalence of sleep apnea in U.S. threatens public health
    Jul 29, 2024 · Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the US.
  100. [100]
    :: Sleep Medicine Research
    Oct 23, 2020 · The male-to-female prevalence ratio is 2–3:1 in the general population, but an 8:1 or greater ratio is observed in clinical settings [8].
  101. [101]
    Sleep-disordered breathing - EMCrit Project
    Mar 5, 2024 · Male sex (2- to 3-fold risk, but differences may diminish >50 years old). ... obstructive sleep apnea (OSA). OSA occurs in 90% of patients ...
  102. [102]
    Impact of Weight Loss on Sleep Apnea
    A 40–90% of people having severe obesity report sleep apnea, and 70% of OSA patients present themselves with obesity (sleep apnea and sleep disruptions in ...Introduction · Weight Loss And Osa · Diet And Osa
  103. [103]
  104. [104]
    The Global Socioeconomic Burden of Obstructive Sleep Apnea
    Aug 26, 2025 · The annual societal cost of untreated OSA in the U.S. now exceeds USD 150 billion, when considering direct medical expenses, productivity losses ...Missing: DALYs | Show results with:DALYs
  105. [105]
    Economic burden of undiagnosed sleep apnea in U.S. is nearly $150B
    Nov 8, 2017 · The estimated costs include $86.9 billion in lost productivity, $26.2 billion in motor vehicle accidents and $6.5 billion in workplace accidents ...
  106. [106]
    Factors influencing patient delay in individuals with obstructive sleep ...
    The upstream factors affecting the patient delay in individuals with OSA include income, place of residence, and objective support.
  107. [107]
    Facilitators and barriers to getting obstructive sleep apnea diagnosed
    These barriers were (1) patients' lack of serious attention to symptoms, (2) patients' negative perceptual framing of diagnosis and treatment of OSA, and (3) ...
  108. [108]
    First Steps Toward Implementing Primary Care Obstructive Sleep ...
    Jul 1, 2025 · Barriers included low self-reported confidence from primary care in the identification and management of OSA; challenges to workflow in the care ...
  109. [109]
    Obstructive Sleep Apnea Screening Health Advisory - AASM
    Sep 16, 2019 · The American Academy of Sleep Medicine recommends an annual OSA screening for all adult patients who have: H – heart failure E – elevated blood pressure A – ...
  110. [110]
    Why sleep apnea deserves priority in public health: a call to action
    Jul 31, 2025 · It is also essential that the World Health Organization recognize OSA as a non-communicable disease linked to reduced quality of life and ...
  111. [111]
    European Respiratory Society statement on advanced telemedicine ...
    Aug 28, 2025 · Telemedicine has applications in all stages of the diagnosis, treatment, and follow-up of patients with obstructive sleep apnoea. It is likely ...
  112. [112]
    Telemedicine-Supported CPAP Therapy in Patients with Obstructive ...
    Jul 29, 2025 · Conclusions: Telemedicine-supported CPAP therapy with structured monthly interventions was associated with substantial clinical improvements, ...
  113. [113]
    OSA underdiagnosis: A World of Difference, a Common Challenge
    Sep 24, 2025 · OSA is a prevalent yet underdiagnosed disease, currently affecting over 50 million adults in the United States, yet up to 80% of cases remained ...
  114. [114]
    Charles Dickens: Impact on Medicine and Society
    The hypothesis raised in this case report was that abnormal chemical drives to breathe caused hypoventilation, and that the resultant hypercapnia was ...
  115. [115]
    Sleep Apnea Syndromes: Central and Obstructive - AccessMedicine
    Sir William Osler in 1918 was credited with first linking the relationship between obesity and Pickwickian syndrome. In the mid-20th century, further work led ...
  116. [116]
    Who was the first to use the term Pickwickian in connection with ...
    The Centennial book of the American Thoracic Society credited Sidney Burwell for the discovery of Obstructive Sleep Apnoea Syndrome. This is only one of the ...
  117. [117]
    William Dement, giant in sleep medicine, dies at 91
    Jun 18, 2020 · Developing polysomnography. Dement also developed polysomnography, which expanded sleep studies beyond eye movements and brain waves to ...
  118. [118]
    The History of Apnea-Hypopnea Index (AHI) - Sleep Institute
    Jul 15, 2025 · Over the years, the AHI has become the benchmark for diagnosing and assessing sleep disordered breathing and has even been codified in laws and ...
  119. [119]
  120. [120]
    Classification of Sleep Disorders - PMC - PubMed Central - NIH
    In 1990, the International Classification of Sleep Disorders (ICSD) was published through the efforts of major international sleep societies at that time, such ...
  121. [121]
    [PDF] ICSD-3-TR - American Academy of Sleep Medicine
    The goals of the International Classification of Sleep. Disorders, third edition, text revision (ICSD-3-TR) were the following: incorporate new information into ...
  122. [122]
    Epidemiology of Pediatric Obstructive Sleep Apnea - PMC - NIH
    In the face of these limitations, estimated population prevalences are as follows: parent-reported “always” snoring, 1.5 to 6%; parent-reported apneic events ...
  123. [123]
    Premarket Approval (PMA) - FDA
    Premarket Approval (PMA) ; INSPIRE II UPPER AIRWAY STIMULATOR · Stimulator, hypoglossal nerve, implanted, apnea · INSPIRE MEDICAL SYSTEMS 9700 63RD AVENUE NORTH
  124. [124]
    Apnimed Reports Positive Topline Results from Second Phase 3 ...
    Jul 23, 2025 · July 23, 2025. LunAIRo, Apnimed's second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea ...
  125. [125]
    Phase 3 Trial Demonstrates Efficacy of First Oral Treatment for ...
    Jul 25, 2025 · For those treated with AD109, 45.0% at week 26 and 47.5% at week 51 showed improved OSA disease severity. 22.9% and 22.5% of those treated with ...
  126. [126]
    Apnimed shares positive results in clinical trial of sleep apnea drug
    May 23, 2025 · On May 19, 2025, Apnimed announced positive topline results from its Phase 3 SynAIRgy clinical trial of AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg).<|separator|>
  127. [127]
    Inspire Upper Airway Stimulation – P130008/S090 - FDA
    Jul 13, 2023 · The approval also increases the upper limit for recommended body mass index (BMI) to 40 (increase from ≤32 to ≤40).Missing: expanded >35
  128. [128]
    [PDF] 2025 - Physician Billing Guide
    The warning label for BMI also increased from 32 to 40. On August 2nd, 2024, Inspire received FDA approval for the Inspire V system. Medicare Coverage. Medicare ...
  129. [129]
    Response to Hypoglossal Nerve Stimulation Changes With Body ...
    Apr 4, 2024 · Medicare guidelines now allow for HGNS device implantation in patients with a BMI of 35 or less. Our findings indicate that while some patients ...
  130. [130]
    Research Story Tip: Gene Therapy Alleviates Obstructive Sleep ...
    Jul 23, 2020 · Now, Johns Hopkins Medicine researchers have shown in mice that they can treat the condition and keep the airway open by using gene therapy to ...
  131. [131]
    New Gene Therapy Study Findings Have Been Reported by ... - Gale
    Aug 16, 2025 · New Gene Therapy Study Findings Have Been Reported by Researchers at Johns Hopkins University (DREADD Approach to Treatment of Sleep Disordered ...
  132. [132]
    Artificial intelligence in obstructive sleep apnea - ScienceDirect.com
    AI can enhance CPAP therapy by automatically adjusting the pressure based on real-time monitoring of the patient's breathing patterns [12]. AI-driven CPAP ...
  133. [133]
    AI-driven sleep apnea screening with overnight blood oxygen ...
    Apr 8, 2025 · The most common pre-processing practice involves using a threshold between 50% and 100% to eliminate hardware errors. However, to determine the ...
  134. [134]
    a feasibility study of didgeridoo training for obstructive sleep apnea
    Jan 25, 2024 · One study found practicing the didgeridoo resulted in reduction in daytime sleepiness in patients with OSA. ... AHI after a structured training ...
  135. [135]
    Didgeridoo playing as alternative treatment for obstructive sleep ...
    In this randomised controlled trial we found that four months of training of the upper airways by didgeridoo playing reduces daytime sleepiness in people with ...Missing: AHI | Show results with:AHI
  136. [136]
    Projecting the 30-year burden of obstructive sleep apnoea in the USA
    Aug 26, 2025 · Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a ...Missing: DALYs | Show results with:DALYs
  137. [137]
    Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. ...
    Aug 27, 2025 · The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and ...Missing: DALYs | Show results with:DALYs
  138. [138]
    Sleep and long COVID: preexisting sleep issues and the risk of post ...
    Recently, obstructive sleep apnea (OSA) has been demonstrated in 2 large studies to be associated with the development of PASC., Although poor sleep quality and ...
  139. [139]
    Incident obstructive sleep apnea in patients with primary ...
    Jun 30, 2025 · This study explores the potential relationship between PA and the risk of developing obstructive sleep apnea (OSA) after a COVID-19 infection.
  140. [140]
    Personalized Medicine Approaches for Obstructive Sleep Apnea
    We define and review the important progress made in understanding and measuring physiological mechanisms (or endotypes) that help define subtypes of OSA.
  141. [141]
    Role of precision medicine in obstructive sleep apnoea
    Jan 5, 2023 · This narrative review summarises the current knowledge of precision medicine in obstructive sleep apnoea, particularly the role of symptom clusters, ...